Conference Correspondent

Conference Correspondent

Large-scale phase 3 clinical trials have already demonstrated the clinical efficacy of belimumab (Benlysta) in patients with systemic lupus erythematosus (SLE), which served as the basis for the US Food and Drug Administration approval of this medication for adult patients with active, autoantibody-positive SLE who are receiving standard therapy.
Belimumab (Benlysta) is a human monoclonal antibody that inhibits B-lymphocyte stimulator that is approved by the US Food and Drug Administration for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
Elevation of interferon type I (IFN-I) is associated with more severe disease in patients with systemic lupus erythematosus (SLE), although the relationship between elevated levels of IFN-I and SLE disease activity over time has not been defined.
Lupus nephritis is frequently associated with a poor long-term prognosis in patients with systemic lupus erythematosus (SLE).
Disease-specific patient-reported outcome (PRO) tools would be useful in the management of a number of rheumatologic conditions, including rheumatoid arthritis (RA), psoriatic arthritis, and systemic lupus erythematosus (SLE).
The pathogenesis of systemic lupus erythematosus (SLE) is characterized by complex immune dysfunction, including aberrant T-cell responses that result in tissue damage and terminal organ failure.
There is evidence from animal models of lupus nephritis that the combination of CTLA4-immunoglobulin (Ig)G plus cyclophosphamide can reverse this disease.
Approximately 50% of patients with systemic lupus erythematosus (SLE) have a serious infection during their disease course, and infections are the leading causes of hospitalization and mortality in these patients.
Increasing evidence suggests common genetic associations across a variety of autoimmune disorders, reflecting genuine susceptibility effects.
Page 10 of 10
Results 91 - 99 of 99
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME